Advertisement
Advertisement
LEGN
Legend Biotech Corporation - ADR
27.99
USDSponsored
-0.13
-0.46%
May 21, 16:00 UTC -4
Closed
After-Market
28.04
+0.05
+0.19%
LEGN Earnings Reports
Positive Surprise Ratio
LEGN beat 9 of 22 last estimates.
41%
Next Report
Date of Next Report
Aug 10, 2026
Estimate for Q2 26 (Revenue/ EPS)
$370.68M
/$0.10
Implied change from Q1 26 (Revenue/ EPS)
+21.49%
/-133.33%
Implied change from Q2 25 (Revenue/ EPS)
+45.33%
/-114.71%
Legend Biotech Corporation - ADR earnings per share and revenue
On May 12, 2026, LEGN reported earnings of -0.30 USD per share (EPS) for Q1 26, missing the estimate of -0.02 USD, resulting in a -1295.35% surprise. Revenue reached 305.10 million, compared to an expected 313.18 million, with a -2.58% difference. The market reacted with a +10.48% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 7 analysts forecast an EPS of 0.10 USD, with revenue projected to reach 370.68 million USD, implying an decrease of -133.33% EPS, and increase of 21.49% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Immunovant, Inc. Common Stock
Report Date
May 20, 2026 For Q4 26
Estimate
-$0.61
Actual
-$0.73
Surprise
-19.11%
Compugen Ltd
Report Date
May 18, 2026 For Q1 26
Estimate
-$0.07
Actual
-$0.08
Surprise
-8.11%
TuHURA Biosciences, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.11
Actual
-$0.13
Surprise
-10.83%
Scilex Holding Company Common Stock
Report Date
May 20, 2026 For Q1 26
Estimate
-Actual
-$4.76
Surprise
-
MiNK Therapeutics, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.78
Actual
-$0.56
Surprise
+27.43%
BioXcel Therapeutics, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.49
Actual
-$0.54
Surprise
-9.16%
Lantern Pharma Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.36
Actual
-$0.30
Surprise
+18.30%
BioCardia, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.16
Actual
-$0.21
Surprise
-24.78%
Akari Therapeutics plc ADR (0.01 USD)
Report Date
May 19, 2026 For Q1 26
Estimate
-$1.40
Actual
-$1.57
Surprise
-11.81%
EVOGENE LTD.
Report Date
May 20, 2026 For Q1 26
Estimate
-$0.27
Actual
-$0.60
Surprise
-117.86%
FAQ
What were Legend Biotech Corporation - ADR's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Legend Biotech Corporation - ADR reported EPS of -$0.30, missing estimates by -1295.35%, and revenue of $305.10M, -2.58% below expectations.
How did the market react to Legend Biotech Corporation - ADR's Q1 2026 earnings?
The stock price moved up 10.48%, changed from $25.58 before the earnings release to $28.26 the day after.
When is Legend Biotech Corporation - ADR expected to report next?
The next earning report is scheduled for Aug 10, 2026.
What are the forecasts for Legend Biotech Corporation - ADR's next earnings report?
Based on 7
analysts, Legend Biotech Corporation - ADR is expected to report EPS of $0.10 and revenue of $370.68M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement